Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 September 2026

CHF
143
million
Cathay Biotech
(Fair value CHF 142.8 million / 6.6% of total assets)
more
CHF
96
million
Dren Bio
(Fair value CHF 96.2 million / 4.5% of total assets)
more
Neurelis
CHF
84
million
(Fair value CHF 84.3 million / 3.9% of net assets)
more
Swixx BioPharma
CHF
80
million
(Fair value CHF 80.0 million / 3.7% of total assets)
more
Argenx
CHF
72
million
(Fair value 72.2 million / 3.3% of total assets)
more
CHF
71
million
Harmony Biosciences
(Fair value 70.5 million / 3.3% of total assets)
more
Natera
CHF
63
million
(Fair value 63.2 million / 2.9% of total assets)
more
ArriVent BioPharma
CHF
62
million
(Fair value CHF 62.2 million / 2.9% of total assets)
more
CHF
55
million
Zymeworks
(Fair value CHF 54.8 million / 2.5 of net assets)
more
Travere Therapeutics
CHF
45
million
(Fair value CHF 44.5 million / 2.1% of total assets)
more